We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Effect of Fetuin A in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00309426
Recruitment Status : Unknown
Verified March 2006 by University of Shizuoka.
Recruitment status was:  Active, not recruiting
First Posted : March 31, 2006
Last Update Posted : May 22, 2006
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to examined the effect of fetuin A on atherosclerosis and prognosis in hemodialysis patients.

Condition or disease
Hemodialysis Malnutrition

Detailed Description:
Fetuin A is known to be a potent inhibitor of ectopic calcification in plasma, and the concentration of fetuin A is closely associated with protein nutritional status. The purpose of this study is to examine whether the plasma concentration of fetuin A is associated with atherosclerosis and 5-year prognosis in hemodialysis patients.

Study Design

Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: The Effect of Serum Fetuin A Concentration on the 5-Year Prognosis in Hemodialysis Patients
Study Start Date : March 2001
Estimated Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hemodialysis for at least 6 months

Exclusion Criteria:

  • Disabled patients
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00309426

Maruyama Hospital
Hamamatsu, Shizuoka, Japan, 430-0001
Sponsors and Collaborators
University of Shizuoka
Maruyama Memorial General Hospital
Study Chair: Hiromichi Kumagai, MD University of Shizuoka
More Information

ClinicalTrials.gov Identifier: NCT00309426     History of Changes
Other Study ID Numbers: CT2006003
First Posted: March 31, 2006    Key Record Dates
Last Update Posted: May 22, 2006
Last Verified: March 2006

Keywords provided by University of Shizuoka:

Additional relevant MeSH terms:
Nutrition Disorders